Kevin Bottomley, Partner, Results Healthcare10.05.21
The last five years has seen the pharmaceutical contract development and manufacturing organization (CDMO) and contract research organization (CRO) sectors blossom in terms of value and significance of merger and acquisition (M&A) transactions. There are many drivers for this, including increased use of pharmaceuticals, retrenching of supply chains to regional and national manufacturing hubs, and novel innovative medicines driving strong investor interest in these business sectors.
CDMO business sector outlook
The CDMO sector benefits from strong growth fundamentals with the increased use of pharmaceuticals in growing and aging populations.
Covid-19 has been the most significant factor in the life sciences industry in the last 24 months. The industry has been seen as a major source of innovative solutions for this pandemic, quickly developing and deploying several highly effective novel vaccines. This has enhanced the public perception of this industry and particularly the pharmaceutical companies. Investors have followed, and life sciences have attracted investment and are viewed as a safe-haven investm
CDMO business sector outlook
The CDMO sector benefits from strong growth fundamentals with the increased use of pharmaceuticals in growing and aging populations.
Covid-19 has been the most significant factor in the life sciences industry in the last 24 months. The industry has been seen as a major source of innovative solutions for this pandemic, quickly developing and deploying several highly effective novel vaccines. This has enhanced the public perception of this industry and particularly the pharmaceutical companies. Investors have followed, and life sciences have attracted investment and are viewed as a safe-haven investm
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
